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Analysis of free fractions for chiral drugs using ultrafast
extraction and multi-dimensional high-performance
affinity chromatography†
Xiwei Zheng, Michelle J. Yoo and David S. Hage*
A multi-dimensional chromatographic approach was developed to
measure the free fractions of drug enantiomers in samples that also
contained a binding protein or serum. This method, which combined
ultrafast affinity extraction with a chiral stationary phase, was
demonstrated using the drugwarfarin and the protein human serum
albumin.
Many drugs and small solutes exist in multiple forms in bio-
logical systems. Drugs are oen reversibly bound to carrier
agents such as serum proteins in the circulatory system, causing
these drugs to exist in two forms: a free fraction and bound
fraction.1–4 Because the free drug fraction is generally thought to
be the biologically-active form,3,4 there has been ongoing
interest in the creation of improved tools for measuring free
drug fractions and for studying drug–protein interactions in
clinical and pharmaceutical samples.1,2,5 The methods of equi-
librium dialysis and ultraltration are oen used for this work
but can have long analysis times and large sample requirements
(e.g., equilibrium dialysis) or can introduce errors due to
nonspecic adsorption to a membrane (e.g., ultraltration or
equilibrium dialysis).6
Chromatographic approaches based on high-performance
affinity chromatography (HPAC) and ultrafast affinity extraction
have recently been proposed as an alternative means for
measuring free drug or free hormone fractions.1,2,7–9 In this type
of approach, small columns containing immobilized anti-
bodies1,2,7,8 or other binding agents, such as immobilized
transport proteins,9 are employed to extract the free form of a
target drug or solute on a time scale that minimizes release of
the target from its protein-bound form in a sample. Potential
advantages of this approach include its speed, small sample
requirements, good precision and low detection limits,
especially when used with detection based on chem-
iluminescence or near-infrared uorescence.1,7,8 However,
previous systems based on this method have been designed to
look at only a specic drug or solute (e.g., warfarin, phenytoin
and thyroxine)1,2,7–9 rather than samples that may contain
multiple or related forms of the same target (e.g., a mixture of
drug enantiomers).
This report describes a multi-dimensional HPAC system that
used ultrafast affinity extraction and chiral chromatography to
simultaneously examine the free forms of drug enantiomers in
complex samples (e.g., serum) and to study the binding of such
drugs with proteins. R/S-Warfarin and its binding protein human
serum albumin (HSA) were used as models to develop and eval-
uate this approach. Warfarin is an anticoagulant that is oen
used as a racemic mixture for the treatment of thromboembolic
diseases, with the R- and S-enantiomers having noticeable
differences in their pharmacokinetics and protein binding
properties.3,10,11 HSA (molar mass, 66.5 kDa) is the main binding
protein for warfarin andmany other drugs in serum and is known
to have strong interactions with both R- and S-warfarin at a region
on this protein known as Sudlow site I.10,12,13
Fig. 1 shows the general separation and analysis strategy that
was used in this study to examine the free fractions of R- and
S-warfarin (see ESI† for experimental details and system cong-
uration). Ultrafast extraction based on an immobilized HSA
microcolumn was rst used to separate the free and protein-
bound fractions of R- and S-warfarin in the presence of a sample
that contained soluble HSA. In this process, the protein-bound
drug and proteins in the sample were eluted in a non-retained
peak from the microcolumn, while the free drug fraction in the
sample was extracted and retained. This retained free drug
fraction was later eluted from the microcolumn under isocratic
conditions and delivered to a second, larger HSA column, which
was utilized as a chiral stationary phase for the separation and
measurement of the captured drug enantiomers.10
Studies were rst performed with this system to nd the
optimum ow rate conditions for extraction of the free fraction of
R/S-warfarin without creating signicant interferences from the
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portion of the drug that was originally bound to sample proteins
but was released as the initial free drug fraction was removed.
Fig. 2 shows the apparent free drug fractions that were obtained
for warfarin–HSA mixtures at various ow rates and at 37 C in
pH 7.4, 0.067 M phosphate buffer when using a 3 mm 2.1 mm
i.d. HSA microcolumn for ultrafast affinity extraction. Based on a
measured protein content of 57 (1) mg HSA per g silica, the
microcolumn was determined to contain 4.0 nmol HSA. The
amount of warfarin applied per injection in Fig. 2 was 0.25% of
the estimated binding capacity. Experiments with injections of
only R/S-warfarin indicated that more than 99% extraction
occurred for this drug's enantiomers under these injection
conditions and at all of the ow rates tested in this study.
In Fig. 2, the apparent free drug fractions that were
measured for a mixture of warfarin with soluble HSA were
elevated at lower ow rates because the longer extraction period
provided in the microcolumn under these conditions allowed
for some dissociation of this drug from its protein-bound
fraction in the sample, as noted previously.1,9 This process was
decreased at higher ow rates and had no signicant effect on
the measured free fractions at a ow rate of 5.0 mL min1 or
higher, which corresponded to a residence time of 100 ms or
less for the sample on the HSA microcolumn.
A second set of studies examined the ability of the multi-
dimensional HPAC system to separate warfarin enantiomers in
the retained free drug fraction (see Fig. 3). Samples containing
1.0 mL of 5 mM warfarin or a 5 mM warfarin–10 mM HSA mixture
were applied to the multi-dimensional system. The upper peak
in Fig. 3(a) was obtained by injecting only warfarin onto the HSA
microcolumn at 5 mL min1. The free fraction of warfarin that
was extracted by this microcolumn eluted with a retention
time of approximately 17–20 s. This gure also shows a
chromatogram that was obtained when the same amount of
warfarin and a two-fold mol excess of soluble HSA were injected
onto the HSA microcolumn under identical conditions. In this
case, a large non-retained peak was now observed at 5–7 s due to
the elution of the soluble HSA and protein-bound fraction of
warfarin. The second retained peak in this case represented the
free fraction of warfarin that was extracted by, and later eluted
from, the HSA microcolumn.
The free warfarin fraction, or a representative portion of this
fraction, that was extracted by the HSA microcolumn was
then eluted in the presence of the pH 7.4 phosphate buffer onto a
5 cm  2.1 mm i.d. HSA column at 0.5 mL min1 for a chiral
separation. The chromatograms in Fig. 3(b) show the peaks that
were obtained for R- and S-warfarin in samples that contained
only racemic warfarin or racemic warfarin plus soluble HSA. With
this combined approach, it was possible to simultaneously study
the free fractions for both R- and S-warfarin in the original
sample. Although the chiral separation obtained with the pH 7.4
buffer in Fig. 3(b) provided baseline resolution for the warfarin
enantiomers and was sufficient for these exploratory studies, the
speed of this latter step could be reduced to less than 10 min by
using a more efficient HSAmonolith column and/or by adding an
organicmodier to themobile phase (see ESI† for examples).10,14,15
The free fraction of R- or S-warfarin in a mixture of racemic
warfarin and soluble HSA was calculated by dividing the
concentration of the enantiomer's free fraction, as represented
by lower peaks in Fig. 3(b), by the concentration measured for
the enantiomer and at the same total sample concentration but
with no soluble protein present, as represented by the upper
peaks in Fig. 3(b). The concentrations of the R- and S-warfarin
fractions were determined by comparing the sizes of these
peaks to those obtained with the same chromatographic system
and using warfarin standards. The free fractions for R- and
S-warfarin in various samples were measured by this approach
based on multi-dimensional HPAC and by employing a refer-
ence method that made use of ultraltration followed by a
Fig. 1 General scheme for separation of the free and protein-bound fractions of
a drug and resolution of the enantiomers in the free drug fraction through the
use of ultrafast extraction and multi-dimensional HPAC.
Fig. 2 Effect of flow rate on the measurement of free fractions in mixtures of
racemic warfarin and HSAwhen using ultrafast affinity extraction. Conditions: 1.0 mL
of 10 mM warfarin or 10 mM warfarin–20 mM HSA injected onto a 3 mm  2.1 mm
i.d. HSA microcolumn.
Fig. 3 Chromatograms for 1.0 mL injections of 5 mM racemic warfarin or 5 mM
racemic warfarin plus 10 mMHSA on (a) an HSAmicrocolumn at 5.0 mLmin1 or (b)
a chiral HSA column at 0.5 mL min1 after sample passage through the HSA
microcolumn. The arrow in (a) shows the time at which a valve was switched to pass
the retained components from the HSA microcolumn onto the larger HSA column
that was used for the chiral separation. These results were obtained at 37 C using
pH 7.4, 0.067 M phosphate buffer as the mobile phase for both columns.
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chiral separation using an HSA column (see ESI† for experi-
mental details). The results that were obtained by each method
are summarized in Table 1.
Table 1 shows that there was good agreement between the
free fractions that were measured in Fig. 3 by the multi-
dimensional HPAC method and by ultraltration followed with
a chiral separation. For a sample that contained 5 mM racemic
warfarin and 10 mM soluble HSA, the absolute difference in
these free fractions was 1–6%, with the results showing no
signicant difference at the 95% condence level. In addition,
these measured free fractions agreed with the range of 33–43%
that was predicted for R- and S-warfarin based on the known
binding constants of this system.9,10
The multi-dimensional HPAC method was also used to
examine other samples. One of these samples contained 30 mM
racemic warfarin and 600 mM HSA, representing a clinically
relevant concentration of HSA and a typical therapeutic concen-
tration for warfarin.16 Good agreement between the multi-
dimensional HPAC system and reference method was again
obtained, with an absolute difference in the measured free frac-
tions of 0.3–0.5% and no signicant differences at the 95%
condence level. In addition, the measured free fractions were
consistent with a range of approximately 0.5–2% that was esti-
mated from the reported binding constants for the warfarin–HSA
interaction.9,10 The free fractions of the warfarin enantiomers
were also examined in human serum that was spiked with a
therapeutic level of this drug. The results for the multi-dimen-
sional HPAC system and reference method were again compa-
rable, with an absolute difference of 0.2–0.5% and no signicant
differences being noted at the 95% condence level.
The multi-dimensional HPAC system was next used as a
screening tool to determine the association equilibrium
constants for R- and S-warfarin with HSA. This was accom-
plished by using the free fraction data along with a single-site
binding model (see ESI† for details). Table 2 shows the results
that were obtained for the 5 mM warfarin–10 mM HSA mixture.
This table also lists previous binding constants that have been
reported for R- and S-warfarin at Sudlow site I of HSA under the
same pH and temperature conditions.10 Under these condi-
tions, the association equilibrium constants that were esti-
mated by multi-dimensional HPAC and the reference methods
continued to show good agreement at the 95% condence level
with one another and with the literature values.
Similar calculations to those used in Table 2 were carried out
for the 30 mM warfarin–600 mM HSA mixture and for the spiked
serum samples (see ESI, Table S1†). The association equilibrium
constants that were obtained by multi-dimensional HPAC and
the reference approach were again consistent with each other;
however, the estimated binding constants were 38–71% smaller
than the literature values. This latter difference is probably due to
the greater uncertainty that was present for these samples in the
measurement of their relatively small free fractions. It is also
possible there were some deviations from a single-site binding
model due to greater nonspecic interactions by warfarin with
the much larger amounts of HSA, and other proteins in the case
of the serum, in this second group of samples.
In summary, it was shown that a multi-dimensional HPAC
system that used ultrafast affinity extraction in combination with
a chiral separation could be used to simultaneously measure the
free fractions of R- and S-warfarin in serum or drug–protein
mixtures. This approach was also used to estimate the binding
constants for these enantiomers with HSA. The results of this
method gave good agreement with a reference method that was
based on ultraltration plus a chiral separation. However, the
multi-dimensional HPAC method had several potential advan-
tages over ultraltration. For instance, this method required only
1 mL of sample per injection and could isolate the free warfarin
fractions within 20–30 s of injection. In comparison, a 1 mL
sample was needed for ultraltration and 1 h was required for the
separation of a free drug fraction by this approach. It was also
possible to directly couple the ultrafast extraction with a chiral
separation to automate and complete both steps using a single
system. This approach is not limited to warfarin or HSA but could
easily be extended to other chiral drugs, or drug mixtures, and
their binding proteins through the use of similar affinity micro-
columns and chiral stationary phases.
We gratefully acknowledge nancial support from the
National Institutes of Health under grant R01 GM044931.
Table 1 Free drug fractions measured for R- and S-warfarin in samples con-
taining soluble HSA or human serum
Sample & Analyte
Measured free fractiona
Multi-dimensional HPAC
Ultraltration +
chiral separation
Racemic warfarin (5 mM) + HSA (10 mM)
R-Warfarin 42 (4)% 41 (4)%
S-Warfarin 38 (5)% 32 (3)%
Racemic warfarin (30 mM) + HSA (600 mM)
R-Warfarin 1.8 (0.8)% 1.5 (0.5)%
S-Warfarin 1.3 (0.2)% 1.8 (0.2)%
Racemic warfarin (30 mM) + human serumb
R-Warfarin 2.7 (1.7)% 2.5 (0.2)%
S-Warfarin 1.1 (0.3)% 1.6 (0.7)%
a These values were obtained at 37 C in pH 7.4, 0.0067 M potassium
phosphate buffer. The numbers in parentheses represent 1 S.D.
(n ¼ 3). b The human serum contained approximately 600 mM HSA.
Table 2 Association equilibrium constants estimated for R- and S-warfarin with
soluble HSA based on a single-site binding model
Sample &
Analyte
Association equilibrium constant, Ka
a (M1)
Multi-dimensional
HPAC
Ultraltration +
chiral separation
Literature
value [ref. 10]
Racemic warfarin (5 mM) + HSA (10 mM)
R-Warfarin 2.0 (0.4)  105 2.1 (0.4)  105 2.1 (0.2)  105
S-Warfarin 2.4 (0.6)  105 3.2 (0.4)  105 2.6 (0.4)  105
a These values were obtained at 37 C in pH 7.4, 0.0067 M potassium
phosphate buffer. The numbers in parentheses represent 1 S.D.
(n ¼ 3).
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EXPERIMENTAL SECTION 
Materials and Reagents.  The HSA (Cohn fraction V, essentially fatty acid free), human 
serum (from male AB plasma, H4522, lot 039K0728; sterile filtered and tested negative for HIV-
1/HIV-2, hepatitis B and hepatitis C), and racemic warfarin (98% pure) were from Sigma (St. 
Louis, MO, USA).  The reagents for the bicinchoninic acid (BCA) protein assay were from 
Pierce (Rockford, IL, USA).  The Nucleosil Si-300 silica (7 m particle diameter, 300 Å pore 
size) was purchased from Macherey Nagel (Dűren, Germany).  All buffers and aqueous solutions 
were prepared using water from a Nanopure system (Barnstead, Dubuque, IA, USA) and were 
passed through Osmonics 0.22 m nylon filters from Fisher (Pittsburgh, PA, USA) 
Apparatus.  The affinity columns were packed using a Prep 24 preparative pump from 
ChromTech (Apple Valley, MN, USA).  The chromatographic system consisted of a PU-2080 
Plus HPLC pump from Jasco (Easton, MD, USA), two six-port Lab Pro valves (Rheodyne, 
Cotati, CA, USA), and a Shimadzu RF-10AXL fluorescence detector (Kyoto, Japan).  An Alltech 
water jacket (Deerfield, IL, USA) and an Isotemp 3013D circulating water bath from Fisher were 
used to maintain a temperature of 37.0 (±0.1) °C for the columns during all experiments 
described in this report.  The chromatographic data were collected and processed using in-house 
programs written in LabView 5.1 (National Instruments, Austin, TX, USA).  The ultrafiltration 
studies were performed using a 5702RH centrifuge from Fisher and tubes containing Ultracel 
YM-T cellulose membranes (30 kDa cut-off), as obtained from Millipore (Billerica, MA, USA). 
Column preparation.  The stationary phase used in these studies consisted of HSA that 
was immobilized on Nucleosil Si-300 silica by the Schiff base, as performed according to the 
literature.1 Control supports were prepared in the same manner but with no HSA being added 
during the immobilization step.  The protein content of the final HSA support was determined in 
Electronic Supplementary Material (ESI) for Analyst
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triplicate by a BCA assay using HSA as the standard and the control support as the blank.   
An HPLC column packer was used to place the supports into stainless steel columns with 
dimensions of 1 cm × 2.1 mm i.d. or 5 cm × 2.1 mm i.d.  The columns with dimension of 3 mm 
× 2.1 mm i.d. used a frit-in-column design, as described in Ref. 2.  The longer columns were 
prepared using traditional stainless steel HPLC housings and end fittings.  The packing solution 
for all of these columns was pH 7.4, 0.067 M potassium phosphate buffer, and the packing 
pressure was 4000 psi (28 MPa). 
Chromatographic studies.  This work utilized a multi-dimensional system in which a 3 
mm  2.1 mm i.d. HSA microcolumn was used for the extraction of free drug fractions and a 5 
cm × 2.1 mm i.d. HSA column was used for chiral separations of the retained free drug fractions.  
The sample loading, injection and column switching were controlled by two separate Rheodyne 
six port valves (Cotati, CA, USA), as illustrated in Fig. S1.  The mobile phase was pH 7.4, 0.067 
M potassium phosphate buffer in the free drug extractions and in the initial chiral separations.  
All samples containing racemic warfarin and HSA were prepared in this buffer and incubated for 
at least 1 h before injection to allow equilibrium to be established between the free and protein-
bound fractions of the drug in the sample.3   
The initial studies examining the free fraction extraction of R- and S-warfarin used a 1.0 
L sample of 10 M racemic warfarin or a 10 M racemic warfarin/20 M HSA mixture that 
was injected onto a 3 mm  2.1 mm i.d. HSA microcolumn at flow rates ranging from 0.5 
mL/min to 6.0 mL/min.  In the final method that was developed in this study, a 1.0 L sample 
injection was made onto the 3 mm  2.1 mm i.d. HSA microcolumn at a flow rate of 5.0 mL/min 
for extraction of the free drug fraction.  Eighteen seconds later, a switching valve was used to 
transfer the eluting free drug fraction to a longer 5 cm × 2.1 mm i.d. HSA column for use in a 
Electronic Supplementary Material (ESI) for Analyst
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chiral separation at 0.5 mL/min.  The aqueous samples used in these latter studies contained 5 
M racemic warfarin or a 5 M warfarin/10 M HSA mixture; 30 M racemic warfarin or 30 
M warfarin/600 M HSA, to examine the use of this method at clinically-relevant 
concentrations; and a mixture of 30 M racemic warfarin and human serum (which contained 
approximately 600 M HSA) to study the feasibility of using this system with human serum 
samples.  The warfarin enantiomers were detected by monitoring their fluorescence at an 
excitation wavelength of 310 nm and an emission wavelength of 390 nm.  The concentrations of 
R- and S-warfarin in each sample were determined by comparing the resulting peak areas to 
those obtained for warfarin standards. 
Ultrafiltration studies.  Before sample introduction, each ultrafiltration device was 
washed three times with 1 mL water and spun at 1500 × g for 5 min.  The devices were then 
washed three times in the same manner with 1 mL of pH 7.4, 0.067 M potassium phosphate 
buffer.  Any remaining buffer in the device was removed by spinning the filtration device at 1500 
× g for 15 min.  Immediately after these washing and pretreatment steps, a 1 mL sample 
containing warfarin or warfarin plus HSA, as prepared in pH 7.4, 0.067 M potassium phosphate 
buffer or human serum, was introduced into three ultrafiltration devices and spun at 1500 × g and 
37ºC for 2.5 min or 6.0 min, respectively (Note: different spinning periods were used to make 
sure that no more than 0.5 mL of the sample passed into the filtrate vial, thus allowing for 
accurate free drug fraction measurements).
4 
 
The resulting filtrates were collected for the measurement of their warfarin 
concentrations by using an HPLC-based chiral separation.  This was accomplished by making a 5 
L injection of each filtrate sample at 1.0 mL/min onto a 1 cm  2.1 mm i.d. HSA column.  The 
mobile phase in this case consisted of pH 7.4, 0.067 M potassium phosphate buffer containing 
Electronic Supplementary Material (ESI) for Analyst
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1.5% (v/v) 1-propanol.  The elution of warfarin enantiomers from this column was again 
monitored by using a fluorescence detector, as described in the previous section, and the 
concentrations of R- and S-warfarin in each filtrate were determined by comparing the resulting 
peaks areas to those that were obtained by the same approach when using warfarin standards.  
Prediction of Free Fractions from Association Equilibrium Constants.  For a drug 
and protein interaction that involves 1:1 binding, the relationship between the theoretical free 
fraction (F) and the association equilibrium constant (Ka) for this interaction can be described by 
using eqs (1) and (2),  
            𝐹 =
𝐶𝑑 − [𝐷−𝑃]     
𝐶𝑑 
     (1) 
𝐾𝑎 =
[𝐷−𝑃]     
(𝐶𝑑 − [𝐷−𝑃])(𝐶𝑝 − [𝐷−𝑃])
         (2) 
in which Cd is the total concentration of drug in the original sample, Cp is the total concentration 
of protein in the sample, [D-P] is the concentration of the drug-protein complex in the original 
sample. 3  
In this study, both R- and S-warfarin were present in a sample containing racemic 
warfarin and both enantiomers were able to interact with any HSA that was present.  Thus, the 
free fractions for these two enantiomers (FR and FS) and their association equilibrium constants 
(Ka,R and Ka,S) were calculated separately, as described by eqs (3)-(6),  
        𝐹𝑅  =
𝐶𝑅  − [𝑅−𝑃]     
𝐶𝑅 
       (3) 
𝐾𝑎,𝑅 =
[𝑅−𝑃]     
(𝐶𝑅 − [𝑅−𝑃])(𝐶𝑝 − [𝑅−𝑃]− [𝑆−𝑃])
    (4) 
         𝐹𝑆  =
𝐶𝑆 − [𝑆−𝑃]     
𝐶𝑆 
       (5) 
𝐾𝑎,𝑆 =
[𝑆−𝑃]     
(𝐶𝑆 − [𝑆−𝑃])(𝐶𝑝 − [𝑅−𝑃]− [𝑆−𝑃])
     (6) 
Electronic Supplementary Material (ESI) for Analyst
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where CR and CS represent the concentrations of R- and S-warfarin in the original sample.  
According to the information provided by their supplier, the R- and S-warfarin were present in 
identical amounts in their original racemic mixture.  Under these conditions, the relationship of 
their concentrations with Cd can be described by eq (7).   
2 CR = 2 CS = Cd        (7) 
In the initial studies examining use of the multi-dimensional HPAC method to measure 
free fractions, the sample consisted of 2.5 M R-warfarin (CR), 2.5 M S-warfarin (CS) and 10 
M HSA (CP).  The association equilibrium constants (Ka,R and Ka,S) of R- and S-warfarin with 
HSA have been reported to be 2.1 (± 0.2) ×105 and 2.6 (± 0.4) ×105 M-1 under the same pH and 
temperature conditions as used in this current study.5  Substituting these values into eqs (3)-(7), 
gave predicted free fractions for R- and S-warfarin of 0.41 (± 0.02) and 0.36 (± 0.03), 
respectively, as found by using the Solver function in Microsoft Excel.  A similar process was 
used to estimate free fractions for the other samples that were examined in this study. 
Estimation of Association Equilibrium Constants from Measured Free Fractions.  
Based on the free drug fractions that were measured in this study, it was possible to estimate the 
overall association equilibrium constants for each drug with HSA.  This was accomplished by 
using the free fraction data and the equations introduced in the previous section.  For instance, by 
using eq (3) the concentration of the R-warfarin/HSA complex ([R-P]) could be calculated from 
the measured free fraction of R-warfarin (FR).  Substituting the value of [R-P] into eq (4) then 
made it possible to obtain Ka,R. 
3 The same process was employed for the calculation of Ka,S by 
using eqs (5) and (6).  The results that were obtained by this process are shown in both Table 2 in 
the main body of the paper and in Table 1S in this Supplementary Information. 
Use of Alternative Conditions for the Chiral Separation of R- and S-Warfarin.  The 
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results shown in Fig. 3(b) in the main body of this paper were based on the use of pH 7.4, 0.067 
M phosphate buffer as a mobile phase for both of the HSA columns in the multi-dimensional 
HPAC system.  This was done for the sake of simplicity in the initial design of this system and 
resulted in the type of separation that is shown in Fig. S2(a) and Fig. 3(b).  However, it was also 
possible to conduct chiral separations by using small amounts of organic modifiers in the mobile 
phase to further improve this separation.  For instance, Fig. S2(b) shows the effects of adding 
1.5% (v/v) 1-propanol to the mobile phase while keeping all of the other conditions the same as 
in Fig. S2(a).  This change lead to a large increase in resolution but lowering the retention factor 
for R-warfarin and increasing the retention factor for S-warfarin, as noted previously for similar 
HSA columns.5   
Other conditions could also be used to improve this chiral separation.  As an example, 
using the same flow rate and amount of 1-propanol as in Fig. S2(b) but decreasing the HSA 
column size to 1 cm × 2.1 mm i.d. still gave baseline resolution between R- and S-warfarin but 
decreased the separation time to around 18 min at 0.50 mL/min, as shown in Fig. S2(c).  Using 
1.5% 1-propanol in the mobile phase and increasing the flow rate to 1.0 mL/min with the 1 cm × 
2.1 mm i.d. HSA column also gave baseline resolution, but with the separation now being 
complete in roughly 9 min (see Fig. S2(d)).  Another way to improve this separation would be to 
use an alternative support, such as a monolith column.  For instance, a separation of R- and S-
warfarin in 6 min was recently reported when using a 1 cm × 4.6 mm i.d. HSA monolith column 
based on a co-polymer of glycidyl methacrylate (GMA) and ethylene glycol dimethacrylate 
(EDMA) that was operated at 2.0 mL/min and that used 0.5% 1-propanol in a pH 7.4, 0.067 M 
phosphate buffer as the mobile phase.6 
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FIGURE LEGENDS 
Fig. S1  Valve configurations used in the multi-dimensional HPAC system. The first valve 
was used for (a) loading and (b) injecting a sample onto an HSA microcolumn for 
a free fraction separation. (c) The second valve was switched when the protein-
bound drug complex and excess protein had been passed through the HSA 
microcolumn and the free drug fraction had just begun to exit this microcolumn. 
The free drug fraction, or a representative portion, was then passed on to a second 
and longer HSA column for a chiral separation. 
 
Fig. S2  Chromatograms for injections of racemic warfarin solution onto HSA columns for 
chiral separation under different conditions.  The results shown in (a) were 
obtained at 0.5 mL/min by injecting 5 L of 30 M racemic warfarin onto 5 cm × 
2.1 mm i.d. HSA column in the mobile phase of pH 7.4, 0.067 M potassium 
phosphate buffer.  The results shown in (b) were obtained for the same sample and 
column with (a) in the mobile phase containing 1.5% 1-propanol as modifier.  The 
results shown in (c) were obtained for the same sample and mobile phase with (b) 
on to a 1 cm × 2.1 mm i.d. HSA column.  The results shown in (d) were obtained 
for the same sample, mobile phase and column with (c) when the flow rate is 1.0 
mL/min.  The HSA columns were prepared by the Schiff base method.  And these 
chromatographic studies were finished at the temperature of 37 ℃. 
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Fig. S1   
(a)	Sample	Loading	
(b)	Sample	Injec on	and	Free	Drug/Protein-Bound	Drug	Separa on	
(a) Sample loading 
) Sa le i j ti   free drug/protein-bound drug separation 
 (c) Chiral separation of free drug fraction
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Table S1.  Association equilibrium constants for R- and S-warfarin with soluble HSA 
 
 
Sample & Analyte 
               Association equilibrium constant, Ka (M
-1
)
a   
 
Multi-dimensional 
HPAC 
Ultrafiltration 
+ chiral separation 
Literature  
value [Ref. 5] 
Racemic warfarin (30 μM) + HSA (600 μM)     
R-Warfarin 1.0 (± 0.4) ×105 1.2 (± 0.4) ×105 2.1 (± 0.2) ×105 
S-Warfarin 1.3 (± 0.2) ×105 0.9 (± 0.1) ×105 2.6 (± 0.4) ×105 
 
Racemic warfarin (30 μM) + Human serumb 
    
R-Warfarin 0.6 (± 0.4) ×105 0.7 (± 0.1) ×105 2.1 (± 0.2) ×105 
S-Warfarin 1.6 (± 0.5) ×105 1.1 (± 0.5) ×105 2.6 (± 0.4) ×105 
 
aThese values were measured for the given samples at 37 oC in pH 7.4, 0.067 M potassium 
phosphate buffer. The numbers in parentheses represent a range of ±1 S.D. Values from Ref. 5 
were measured under the same conditions by using frontal analysis. 
bThe human serum contained approximately 600 M HSA. 
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